—Yes, say the authors of a new study, which found that a mere 5% of routine follow-up visits among patients with diffuse large B-cell lymphoma (DLBCL) in remission resulted in detection of relapse.

During a Case-Based Roundtable® event, Natalie Galanina, MD, reviewed how outcomes have changed in patients with primary ...

In the ECHELON-3 study, the brentuximab vedotin combination with lenalidomide and rituximab reduced mortality risk by 37% compared with placebo.

An early pilot trial suggests that combining atezolizumab (tecectriq) with rituximab (Rituxan), gemcitabine (gemzar) and ...

Combining epcoritamab-bysp with standard chemotherapy significantly improved response for patients with relapsed/refractory DLBCL. The regimen also significantly extended survival. The addition of ...

Enhanced assay granted approval by New York State’s Clinical Lab Evaluation Program (CLEP) for patients with DLBCL clonoSEQ is the only DLBCL MRD ...

Each year in Europe, an estimated 38,000 people are diagnosed with DLBCL. 4,5 Approximately four out of ten patients will relapse after first line treatment and the majority of patients who ...

Matthew Matasar, MD, discussed what the findings from the ELM-1 trial of odronextamab in diffuse large B-cell lymphoma mean ...

Princeton: Bristol Myers Squibb has announced that the European Commission (EC) has granted approval to Breyanzi ...

Antengene’s new drug application (NDA) for Xpovio (selinexor) has gained approval from the Indonesia National Agency of Drug ...

More than 18,000 people are diagnosed with DLBCL each year. About 30–40% of patients will experience relapse, most of them within the first two years. MRD testing can help doctors assess ...